Haemonetics Corp
NYSE:HAE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
71.16
97.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HAE stock under the Base Case scenario is 99.89 USD. Compared to the current market price of 85.55 USD, Haemonetics Corp is Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Haemonetics Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HAE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Haemonetics Corp
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Haemonetics Corp
Balance Sheet Decomposition
Haemonetics Corp
Current Assets | 955.9m |
Cash & Short-Term Investments | 299.3m |
Receivables | 213.5m |
Other Current Assets | 443.1m |
Non-Current Assets | 1.6B |
PP&E | 300.5m |
Intangibles | 1.1B |
Other Non-Current Assets | 164.8m |
Current Liabilities | 273.9m |
Accounts Payable | 69.2m |
Accrued Liabilities | 49.3m |
Other Current Liabilities | 155.4m |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 1.2B |
Other Non-Current Liabilities | 152.9m |
Earnings Waterfall
Haemonetics Corp
Revenue
|
1.4B
USD
|
Cost of Revenue
|
-625.9m
USD
|
Gross Profit
|
735.3m
USD
|
Operating Expenses
|
-520.2m
USD
|
Operating Income
|
215m
USD
|
Other Expenses
|
-91.2m
USD
|
Net Income
|
123.8m
USD
|
Free Cash Flow Analysis
Haemonetics Corp
USD | |
Free Cash Flow | USD |
Haemonetics achieved a second quarter revenue of $346 million, representing a 9% increase year-over-year. Adjusted earnings per share rose 13% to $1.12. The company raised its organic revenue growth guidance from 1-3% to 1-4% for the fiscal year 2025. The adjusted operating margin guidance remained between 23-24%, amid expanding hospital business and product uptake. Notably, plasma revenue is projected to decline 3-6%, influenced by a $100 million contribution from CSL. Conversely, Haemonetics anticipates a strong 31% growth in hospital revenue, driven by innovative products like the VASCADE MVP XL. The firm maintains a focus on shareholder returns, with ongoing stock buybacks.
What is Earnings Call?
HAE Profitability Score
Profitability Due Diligence
Haemonetics Corp's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Haemonetics Corp's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
HAE Solvency Score
Solvency Due Diligence
Haemonetics Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Haemonetics Corp's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HAE Price Targets Summary
Haemonetics Corp
According to Wall Street analysts, the average 1-year price target for HAE is 113.02 USD with a low forecast of 85.85 USD and a high forecast of 131.25 USD.
Dividends
Current shareholder yield for HAE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
HAE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.
Contact
IPO
Employees
Officers
The intrinsic value of one HAE stock under the Base Case scenario is 99.89 USD.
Compared to the current market price of 85.55 USD, Haemonetics Corp is Undervalued by 14%.